-- Completion of Adelia milestones marks promising path toward clinical drug development -- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psy
Approval follows the positive opinion granted by European Committee for Medicinal Products for Human Use (CHMP) in July 2022 LUPKYNIS is the first oral medicine approved in both the U.S. and Europe for the treatment of adults living with active lupus ne
DUBLIN--(BUSINESS WIRE)--The "Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report by Disease Type (Neurological, CVDs), by Specialty (Molecular, Biochemical), by Technology (NGS, PCR-based), by End Use, and Segment Forecasts, 2022
DUBLIN--(BUSINESS WIRE)--The "Automated and Rapid Microbiological Tests - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Automated and Rapid Microbiological Tests Market to Reach $7.6 Billion
Independent proxy advisory firm Glass Lewis recommends that Zymeworks shareholders vote FOR the Redomicile resolution Glass Lewis notes Zymeworks has made a compelling case that the Redomicile will favor the Company on the basis of more favorable corp
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intak
VANCOUVER, British Columbia--(BUSINESS WIRE)--Life Sciences BC (LSBC) is pleased to announce new and returning members to the Board of Directors, following its Annual General Meeting (AGM) held on September 15th, 2022. The incoming Board of Directors is c
BEIJING & GUANGZHOU, China--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based thera
- FDA clears IND of First-In-Class, Peripherally-Acting CB1 Inverse Agonist INV-202 - Phase 2 trial in Diabetic Kidney Disease will also provide data in complications of diabetes, metabolic syndrome and dyslipidemia MONTREAL--(BUSINESS WIRE)--#CB1--Inve
Revenue Exceeded $1.1 Million for the Period Ended July 31, 2022 VANCOUVER, British Columbia--(BUSINESS WIRE)--Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.